Advertisement
Research Article| Volume 378, P64-68, July 15, 2017

NUDT15 p.R139C variant is common and strongly associated with azathioprine-induced early leukopenia and severe alopecia in Korean patients with various neurological diseases

Published:April 26, 2017DOI:https://doi.org/10.1016/j.jns.2017.04.041

      Highlights

      • Genetic variance of TPMT is not a determinant for AZA-induced leukopenia in Korea
      • In Korea, the NUDT15 p.R139C variant is common and may predict AZA-induced leukopenia
      • Also, this variant of homozygote primarily serves as a risk factor for early rather than late-developing leukopenia of severe grade, along with the associated alopecia.

      Abstract

      Azathioprine (AZA)-induced leukopenia is a relatively common complication in Korean patients. In addition to variation in TPMT (thiopurine S-methyltransferase), the NUDT15 p.R139C variant was recently identified to have a strong association with AZA-induced leukopenia. We investigated these associations in Korean patients undergoing AZA treatment with various neurological diseases. Among 84 enrolled patients, 20 (23.8%; 7 early, 13 late) exhibited leukopenia. The NUDT15 p.R139C variant was associated with leukopenia (OR: 11.844, 95% CI 3.984–36.024, p = 1.327 × 10−5). The allelic frequency of NUDT15 p.R139C was as high as 10.7% and the frequency of the C/C, C/T, and T/T genotypes was 84.5, 10.7, and 5.9%, respectively. All T/T homozygous patients (5/5) developed early severe-grade leukopenia (white blood cells <1000 mm−3) and severe alopecia. NUDT15 p.R139C was strongly associated with early leukopenia and severe alopecia (OR for early leukopenia: 107.624, 95% CI 18.857–614.250, p = 1.403 × 10−7, OR for severe alopecia: 77.152, 95% CI 17.378–342.526, p = 1.101 × 10−8). The sensitivity and specificity for predicting AZA-induced early leukopenia were 85.7% and 92.2%, respectively. Therefore, the NUDT15 p.R139C variant is common and strongly associated with AZA-induced early leukopenia and severe alopecia in Korean patients with various neurological diseases.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Anstey A.
        • Lear J.T.
        Azathioprine: clinical pharmacology and current indications in autoimmune disorders.
        BioDrugs. 1998; 9: 33-47
        • Black A.J.
        • McLeod H.L.
        • Capell H.A.
        • Powrie R.H.
        • Matowe L.K.
        • Pritchard S.C.
        • Collie-Duguid E.S.
        • Reid D.M.
        Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine.
        Ann. Intern Med. 1998; 129: 716-718
        • Collie-Duguid E.S.
        • Pritchard S.C.
        • Powrie R.H.
        • Sludden J.
        • Collier D.A.
        • Li T.
        • McLeod H.L.
        The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations.
        Pharmacogenetics. 1999; 9: 37-42
        • Colombel J.F.
        • Ferrari N.
        • Debuysere H.
        • Marteau P.
        • Gendre J.P.
        • Bonaz B.
        • Soule J.C.
        • Modigliani R.
        • Touze Y.
        • Catala P.
        • Libersa C.
        • Broly F.
        Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.
        Gastroenterology. 2000; 118: 1025-1030
        • Kim M.J.
        • Choe Y.H.
        Monitoring and safety of azathioprine therapy in inflammatory bowel disease.
        Pediatr. Gastroenterol. Hepatol. Nutr. 2013; 16: 65-70
        • Kim J.H.
        • Cheon J.H.
        • Hong S.S.
        • Eun C.S.
        • Byeon J.S.
        • Hong S.Y.
        • Kim B.Y.
        • Kwon S.H.
        • Kim S.W.
        • Han D.S.
        • Yang S.K.
        • Kim W.H.
        Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study.
        J. Clin. Gastroenterol. 2010; 44: e242-e248
        • Gearry R.B.
        • Barclay M.L.
        • Burt M.J.
        • Collett J.A.
        • Chapman B.A.
        Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.
        Pharmacoepidemiol. Drug Saf. 2004; 13: 563-567
        • Connell W.R.
        • Kamm M.A.
        • Ritchie J.K.
        • Lennard-Jones J.E.
        Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.
        Gut. 1993; 34: 1081-1085
        • Yang S.K.
        • Hong M.
        • Baek J.
        • Choi H.
        • Zhao W.
        • Jung Y.
        • Haritunians T.
        • Ye B.D.
        • Kim K.J.
        • Park S.H.
        • Park S.K.
        • Yang D.H.
        • Dubinsky M.
        • Lee I.
        • McGovern D.P.
        • Liu J.
        • Song K.
        A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia.
        Nat. Genet. 2014; 46: 1017-1020
        • Asada A.
        • Nishida A.
        • Shioya M.
        • Imaeda H.
        • Inatomi O.
        • Bamba S.
        • Kito K.
        • Sugimoto M.
        • Andoh A.
        NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease.
        J. Gastroenterol. 2016; 51: 22-29
        • Kakuta Y.
        • Naito T.
        • Onodera M.
        • Kimura T.
        • Shiga H.
        • Endo K.
        • Negoro K.
        • Kinouchi Y.
        • Shimosegawa T.
        NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD.
        Pharmacogenomics J. 2016; 16: 280-285
        • Lee Y.J.
        • Hwang E.H.
        • Park J.H.
        • Shin J.H.
        • Kang B.
        • Kim S.Y.
        NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn's disease.
        Eur. J. Gastroenterol. Hepatol. 2016; 28: 475-478
        • Ansari A.
        • Arenas M.
        • Greenfield S.M.
        • Morris D.
        • Lindsay J.
        • Gilshenan K.
        • Smith M.
        • Lewis C.
        • Marinaki A.
        • Duley J.
        • Sanderson J.
        Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.
        Aliment. Pharmacol. Ther. 2008; 28: 973-983
        • Institute NC
        Common Terminology Criteria for Adverse Events v4.0.
        2009
        • Ito K.
        • Hirao A.
        • Arai F.
        • Takubo K.
        • Matsuoka S.
        • Miyamoto K.
        • Ohmura M.
        • Naka K.
        • Hosokawa K.
        • Ikeda Y.
        • Suda T.
        Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells.
        Nat. Med. 2006; 12: 446-451
        • Zhao J.
        • Li H.
        • Zhou R.
        • Ma G.
        • Dekker J.D.
        • Tucker H.O.
        • Yao Z.
        • Guo X.
        Foxp1 regulates the proliferation of hair follicle stem cells in response to oxidative stress during hair cycling.
        PLoS One. 2015; 10: e0131674
        • Takagi Y.
        • Setoyama D.
        • Ito R.
        • Kamiya H.
        • Yamagata Y.
        • Sekiguchi M.
        Human MTH3 (NUDT18) protein hydrolyzes oxidized forms of guanosine and deoxyguanosine diphosphates: comparison with MTH1 and MTH2.
        J. Biol. Chem. 2012; 287: 21541-21549
        • McLennan A.G.
        The Nudix hydrolase superfamily.
        Cell. Mol. Life Sci. 2006; 63: 123-143